Streetbeat News

Products Services

AAPL

Despite a 5% drop in Apple Inc. (AAPL) shares in 2024 due to weaker consumer demand and Chinese market restrictions, Neuberger Berman analyst Daniel Flax believes Apple is set for long-term success. Flax highlighted Apple's history of product reinvention, expansion in wearables and services, and potential in spatial computing with VisionPro hardware. He also noted a trend towards consumers choosing higher-end iPhone models and predicted further integration of AI in Apple's products.

Portfolio Pulse from Erica Kollmann

January 04, 2024 | 9:54 pm

DRMA

Dermata Therapeutics, Inc. (DRMA) shares have risen following the announcement of a new Japanese patent for its DMT410 program, aimed at treating hyperhidrosis.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:38 pm

V

Visa Inc (NYSE:V) has announced the launch of its Web3 Loyalty Engagement Solution, aimed at transforming customer engagement through innovative digital experiences. The platform enables brands to offer gamified giveaways, augmented reality treasure hunts, and unique digital collectibles as rewards. Visa's research indicates a consumer preference for real-world and personalized experiences. The solution is powered by SmartMedia Technologies, allowing brands to create customized experiences and offers with a digital wallet feature for various sectors.

Portfolio Pulse from Murtuza Merchant

January 04, 2024 | 9:36 pm

ARKK

KRE

NVDA

TSLA

Matthew Tuttle, CEO of Tuttle Capital Management, has filed for six new leveraged and inverse Bitcoin ETFs. These ETFs are designed for short-term trading and are not recommended for non-active investors. Tuttle previously launched ETFs that bet against Cathie Wood's ARKK and Jim Cramer's stock recommendations. Additionally, Tuttle Capital launched leveraged and inverse ETFs for Tesla and NVIDIA in October 2023, with nearly $100 million in assets under management. Tuttle also introduced the SKRE ETF, which offers a leveraged inverse investment option against regional banks, following Cramer's recommendation of SVB Financial Group before its collapse.

Portfolio Pulse from Chris Katje

January 04, 2024 | 9:29 pm

ALLO

Allogene Therapeutics has partnered with Foresight Diagnostics to develop an MRD-based in-vitro diagnostic for use in the ALPHA3 trial, which is aimed at frontline consolidation in large B-cell lymphoma. The partnership will leverage Foresight's ultra-sensitive MRD technology to identify suitable patients for enrollment in the trial.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:18 pm

PSN

Parsons Corporation has partnered with the Port of Oakland, Advent eModal, Mobile Programming, and other key stakeholders to launch the Freight Intelligent Transportation System (FITS) at the Port of Oakland. This system aims to enhance the efficiency of freight movement and improve traffic management.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:14 pm

DRMA

Dermata Therapeutics, Inc. has announced the issuance of a patent in Japan for its DMT410 program, which is designed for the treatment of hyperhidrosis, a condition characterized by excessive sweating. This patent strengthens the company's intellectual property position and potentially opens up opportunities in the Japanese market for its hyperhidrosis treatment.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:13 pm

RPTX

Debiopharm and Repare Therapeutics have announced a partnership to conduct a clinical study exploring a new combination therapy for cancer treatment. The study will focus on the combined effect of Debio 0123, a WEE1 inhibitor by Debiopharm, and lunresertib, a PKMYT1 inhibitor developed by Repare Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:11 pm

ALLO

Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its 2024 Platform Vision, focusing on allogeneic CAR T products for cancer and autoimmune diseases. The ALPHA3 trial aims to establish cemacabtagene ansegedleucel (cema-cel) as a frontline treatment for Large B-Cell Lymphoma (LBCL) patients with minimal residual disease (MRD). The ALPHA2 trial in Chronic Lymphocytic Leukemia (CLL) and the ALLO-329 program for Autoimmune Disease (AID) are also highlighted. The TRAVERSE trial with ALLO-316 in Renal Cell Carcinoma (RCC) is advancing with a new treatment algorithm. Allogene's manufacturing facility, Cell Forge 1, is expected to meet future demand for AlloCAR T products. The company plans to reduce cash burn and extend its financial runway into 2026. A conference call is scheduled to discuss the vision, and Dr. Chang will present at the J.P. Morgan Healthcare Conference.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:09 pm

FUSN

Fusion Pharmaceuticals announced that it has reached an agreement with the FDA on a protocol and development plan for its investigational drug FPI-2265.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 9:08 pm